中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (10): 809-814.doi: 10.19401/j.cnki.1007-3639.2017.10.008

• 论著 • 上一篇    下一篇

同侧多原发灶乳腺癌病灶间异质性的研究

王歆光1,刘毅强2,何英剑1,解云涛1   

  1. 1. 北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺中心,恶性肿瘤发病机制及转化研究教育部重点实验室,北京 100142 ;
    2. 北京大学肿瘤医院暨北京市肿瘤防治研究所病理科,恶性肿瘤发病机制及转化研究教育部重点实验室,北京 100142
  • 出版日期:2017-10-30 发布日期:2017-12-05
  • 通信作者: 解云涛 Email:yuntaoxie@hotmail.com

Intertumoral heterogeneity in patients with ipsilateral multifocal/multicentric breast cancer diagnosed by core needle biopsy

WANG Xinguang1, LIU Yiqiang2, HE Yingjian1, XIE Yuntao1   

  1. 1. Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing, Breast Center, Peking University Cancer Hospital and Institute, Beijing 100142, China; 2. Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing, Department of Pathology, Peking University Cancer Hospital and Institute, Beijing 100142, China
  • Published:2017-10-30 Online:2017-12-05
  • Contact: XIE Yuntao E-mail: yuntaoxie@hotmail.com

摘要: 背景与目的:同侧多原发灶乳腺癌临床并不鲜见,既往对于病灶间异质性的研究多数基于术后标本。本研究比较了术前空芯针穿刺确诊的同侧多原发灶乳腺癌病灶间的异质性,探讨其对临床决策的影响。方法:回顾性分析北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺中心2013-2016年间空芯针穿刺确诊的同侧多原发灶乳腺癌资料,比较不同病灶组织学及雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)、人表皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)和Ki-67等免疫组织化学结果的异质性,并根据免疫组织化学结果判定病灶分子分型。结果:共75例同侧多原发灶乳腺癌纳入本研究。已完成腋窝评价的69例患者中腋窝淋巴结阳性51例(68.0%)。9例(12.0%)病灶间组织学类型和组织学分级存在异质性。ER、PR、HER-2和Ki-67结果病灶间存在异质性的患者分别为1例(1.3%)、10例(13.3%)、1例(1.3%)和9例(12.0%)。10例(13.3%)病灶之间分子分型存在异质性。按照现行指南进行免疫组织化学检查,4例(5.3%)治疗决策可能会受到影响。结论:空芯针穿刺确诊同侧多原发灶乳腺癌病灶间组织学结果及免疫组织化学结果存在异质性,仅对主要病灶进行免疫组织化学检测可能影响部分患者的治疗决策。

关键词: 乳腺癌, 多灶, 多中心, 肿瘤异质性, 分子分型

Abstract: Background and purpose: Multifocal/multicentric (MF/MC) breast cancer is frequently encountered in clinical practice. Most studies comparing the heterogeneity of lesions are based on pathological outcomes after upfront surgery. We sought to describe the histological and immunohistochemical characteristics of each lesion in patients with MF/MC breast cancer diagnosed by core needle biopsy. Methods: We retrospectively reviewed the tumor type, grade, and immunohistochemical characteristics [estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2) and Ki-67] of ipsilateral MF/MC breast cancer patients and assessed the heterogeneity among the lesions. Molecular phenotype was determined by immunohistochemistry. Results: A total of 75 MF/MC breast cancer patients were included. At the time of the manuscript writing, 51 patients proved to be lymph node positive either by fine needle aspiration cytology or sentinel lymph node biopsy. Intertumoral heterogeneity in tumor type and grade was detected in 9 of 75 patients (12.0%). Intertumoral heterogeneity in ER, PR, HER-2 and Ki-67 was detected in 1 (1.3%), 10 (13.3%), 1 (1.3%) and 9 (12.0%) patients, respectively. Intertumoral heterogeneity in molecular phenotype was detected in 10 patients (13.3%). Immunohistochemistry tests carried out according to current guideline may result in suboptimal treatment in 4 patients (5.3%). Conclusion: Histological and immunohistochemical heterogeneity can be found among lesions of ipsilateral MF/MC breast cancer diagnosed by core needle biopsy. Immunohistochemistry tests carried out in the index tumor only may result in suboptimal treatment in these patients.

Key words: Breast neoplasms, Multifocality, Multicentricity, Intertumoral heterogeneity, Molecular phenotype